5,643.00
-41(-0.72%)
Currency In JPY
Address
14, Nishinosho-Monguchi-cho
Kyoto, 601-8550
Japan
Phone
81 7 5321 1111
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2213
First IPO Date
January 01, 2001
| Name | Title | Pay | Year Born |
| Hayato Wada | Corporate Officer & Department Manager of Kansai Business Office | 0 | N/A |
| Kazuyuki Iwata | Director of Sales and Marketing & Director | 0 | 1966 |
| Manabu Beppu | Corporate Officer and Head of R & D Planning and Administration Dept. | 0 | N/A |
| Masaya Toda | Head of Licensing & Alliance Division and Corporate Officer | 0 | N/A |
| Hideyuki Fujii | Accounting & Finance Department Manager | 0 | N/A |
| Hitoshi Ishizawa | GM of Functional Food Division & Director | 0 | 1961 |
| Takanori Edamitsu | Head of Business Management & Sustainability and Director | 0 | 1963 |
| Takashi Takaya | GM of Personnel, General Affairs, Risk Mgmt, Compliance & Digital Trans and Director | 0 | 1960 |
| Toru Nakai | President & Director | 0 | 1971 |
| Yoko Nakanishi | Corporate Officer & Department Manager of Human Resources Dept. | 0 | N/A |
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.